icon-folder.gif   Conference Reports for NATAP  
  53rd ICAAC Interscience Conference on
Antimicrobial Agents and Chemotherapy
September 10-13, 2013, Denver CO
Back grey_arrow_rt.gif
Multicentre Open-Label Study of Switching from Atripla to Eviplera for Possible Efavirenz Associated CNS Toxicity*
  Reported by Jules Levin
ICAAC 2013 Sept 10-13 Denver CO
M.Nelson1,2, A.Winston2, L.Waters3, C.Higgs1, M.Roche4, B.Mora-Peris2, A.Milincovic3, S.Mandalia2, H.M.Yapa1, M.Fisher4 1Chelsea & Westminster Hospital, London, UK; 2Imperial College School of Medicine, London, UK; 3Mortimer Market Clinic, London, UK; 4Brighton & Sussex University Hospitals, UK




References: [1] Waters L et al. AIDS 2011;25:65-71. [2] Scourfield A et al. AIDS 2012; 26:1399-1401. [3] Efavirenz Summary of Product Characteristics, 2013. [4] Molina JM et al. Lancet 2011; 378: 238-46. [5] Cohen CJ et al.. Lancet 2011; 378: 229-37.